U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H27NO
Molecular Weight 369.4987
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of JWH-210

SMILES

CCCCCN1C=C(C(=O)C2=CC=C(CC)C3=C2C=CC=C3)C4=C1C=CC=C4

InChI

InChIKey=LACIUQLUNACUKC-UHFFFAOYSA-N
InChI=1S/C26H27NO/c1-3-5-10-17-27-18-24(22-13-8-9-14-25(22)27)26(28)23-16-15-19(4-2)20-11-6-7-12-21(20)23/h6-9,11-16,18H,3-5,10,17H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C26H27NO
Molecular Weight 369.4987
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19249138 | https://www.ncbi.nlm.nih.gov/pubmed/28828742

JWH-210 is an analgesic chemical from the naphthoylindole family, which acts as a potent cannabinoid agonist at both the CB1 and CB2 receptors. JWH-210 is one of the most potent 4-substituted naphthoyl derivatives in the naphthoylindole series, having a higher binding affinity. The physiological and toxicological properties of this compound have not been evaluated in humans.

CNS Activity

Curator's Comment: Known to be CNS penetrant in Pigs, Mice. Human data not available.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.46 nM [Ki]
0.69 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

Mice were treated with JWH-210 (10 mg/kg, 3 days, i.p.)
Route of Administration: Intraperitoneal
Splenocytes were cultured from naïve mice as mentioned previously. The cells were seeded in 96-well plates (5 × 10^5 cells/ well) with 100 μL media. After seeding single cell suspensions, the plates were incubated for 6 h in 95% air:5% CO2 using standard culture methods. To confirm cell viability by synthetic cannabinoids, the splenocytes were treated with synthetic cannabinoids (0, 1, 10, and 100 μM) for 16 h. To observe relationship between JWH-210 and CB receptors, the splenocytes were treated with media or JWH-210 or JWH-210/CB receptor antagonist (rimonabant or AM630) for 4 h.
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:40:34 UTC 2023
Edited
by admin
on Sat Dec 16 08:40:34 UTC 2023
Record UNII
R18JYO04PY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
JWH-210
Common Name English
J2.929.916A
Code English
METHANONE, (4-ETHYL-1-NAPHTHALENYL)(1-PENTYL-1H-INDOL-3-YL)-
Systematic Name English
4-ETHYLNAPHTHALEN-1-YL-(1-PENTYLINDOL-3-YL)METHANONE
Systematic Name English
Classification Tree Code System Code
WIKIPEDIA Designer-drugs-JWH-210
Created by admin on Sat Dec 16 08:40:34 UTC 2023 , Edited by admin on Sat Dec 16 08:40:34 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID301010019
Created by admin on Sat Dec 16 08:40:34 UTC 2023 , Edited by admin on Sat Dec 16 08:40:34 UTC 2023
PRIMARY
PUBCHEM
45270396
Created by admin on Sat Dec 16 08:40:34 UTC 2023 , Edited by admin on Sat Dec 16 08:40:34 UTC 2023
PRIMARY
CAS
824959-81-1
Created by admin on Sat Dec 16 08:40:34 UTC 2023 , Edited by admin on Sat Dec 16 08:40:34 UTC 2023
PRIMARY
WIKIPEDIA
JWH-210
Created by admin on Sat Dec 16 08:40:34 UTC 2023 , Edited by admin on Sat Dec 16 08:40:34 UTC 2023
PRIMARY
FDA UNII
R18JYO04PY
Created by admin on Sat Dec 16 08:40:34 UTC 2023 , Edited by admin on Sat Dec 16 08:40:34 UTC 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY